Pseudoprogression as an adverse event of glioblastoma therapy.

about

Pseudoprogression as an adverse event of glioblastoma therapy.

Item

http://www.wikidata.org/entity/Q47164037

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pseudoprogression as an adverse event of glioblastoma therapy.

@en

Pseudoprogression as an adverse event of glioblastoma therapy.

@nl

type

Item

label

Pseudoprogression as an adverse event of glioblastoma therapy.

@en

Pseudoprogression as an adverse event of glioblastoma therapy.

@nl

prefLabel

Pseudoprogression as an adverse event of glioblastoma therapy.

@en

Pseudoprogression as an adverse event of glioblastoma therapy.

@nl

P1476

Pseudoprogression as an adverse event of glioblastoma therapy.

@en

P2093

Anna Estival

http://www.w3.org/2001/XMLSchema#string

Carlos Mesia

http://www.w3.org/2001/XMLSchema#string

Cristina Carrato

http://www.w3.org/2001/XMLSchema#string

Estela Pineda

http://www.w3.org/2001/XMLSchema#string

Eugenia Verger

http://www.w3.org/2001/XMLSchema#string

Francesc Alameda

http://www.w3.org/2001/XMLSchema#string

GLIOCAT Group

http://www.w3.org/2001/XMLSchema#string

Jaume Capellades

http://www.w3.org/2001/XMLSchema#string

Jordi Craven-Bartle

http://www.w3.org/2001/XMLSchema#string

Jordi Marruecos

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.

The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence

Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.

Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.

Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.

Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.

P304

2858-2866

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.1242

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Carmen Balaña

Laura Oleaga

Maria Martinez Garcia

P577

2017-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29105360

http://www.w3.org/2001/XMLSchema#string

P932

5727237

http://www.w3.org/2001/XMLSchema#string